Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05048368 | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function | withdrawn | Phase 1 | 0 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05041335 | Wet Heparinized Suction for Abdominal Cancer(EUS Heparin) | withdrawn | N/A | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | withdrawn | Phase 1 / Phase 2 | 0 | Institut de Recherches Internationales ServierOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT05067842 | Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma(TRACT DNA) | withdrawn | — | 0 | Medical College of WisconsinOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | withdrawn | — | 0 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05898828 | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2024 | clinicaltrials |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT04272268 | Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce Respiratory Complications(Hi-FLO) | withdrawn | — | 0 | University Hospitals of North Midlands NHS TrustOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02017366 | Design of the EFECTS Trial(EFECTS) | withdrawn | N/A | 0 | University Hospital, GasthuisbergOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04835987 | Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer(PROSNACO) | withdrawn | — | 0 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02716688 | S-1 and Radiotherapy for Elderly Esophageal Cancer Patients | withdrawn | Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT03991104 | SOX-based CRT for Esophageal Cancer. | withdrawn | Phase 1 / Phase 2 | 0 | Zhejiang Provincial People's HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05245760 | ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer(CRATER) | withdrawn | Phase 2 | 0 | Zhonglin HaoOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | withdrawn | Phase 2 | 0 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04520867 | STRENGTH Expansion | withdrawn | — | 0 | University of Colorado, DenverOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | withdrawn | N/A | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 27, 2021 | clinicaltrials |
| NCT02857218 | Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 16, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02326779 | Low-dose Aspirin Therapy for Esophageal Cancer | withdrawn | Phase 3 | 0 | Zhejiang UniversityOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03818997 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer(DYNAMIC) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT03110939 | Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer | withdrawn | N/A | 0 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01498757 | Genome-wide Association Study | withdrawn | — | 0 | Samsung Medical CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00372450 | Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer | withdrawn | N/A | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT03234842 | Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer(ES01) | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02274012 | Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 14, 2017 | clinicaltrials |
| NCT02843750 | Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT02689401 | MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT02598687 | Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. | withdrawn | Phase 1 | 0 | Maastricht Radiation OncologyOTHER | 0 | Apr 21, 2016 | clinicaltrials |
| NCT02491372 | A Pilot Study of the Effectiveness of Acceptance and Commitment Therapy With a Post-Upper GI Cancer Population | withdrawn | N/A | 0 | Martin DempsterOTHER | 0 | Apr 5, 2016 | clinicaltrials |
| NCT01998347 | Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer | withdrawn | Phase 3 | 0 | Shantou University Medical CollegeOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01301495 | Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02034968 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02041819 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02011594 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT02205463 | KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer | withdrawn | Phase 1 | 0 | NYU Langone HealthOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT01627080 | Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 28, 2014 | clinicaltrials |
| NCT01256203 | Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light | withdrawn | Phase 2 | 0 | Pinnacle Biologics Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00636298 | Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Nov 19, 2013 | clinicaltrials |
| NCT00025532 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer | withdrawn | Phase 1 | 0 | University of California, San FranciscoOTHER | 1 | Sep 14, 2012 | clinicaltrials |
| NCT01203163 | Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes(CALIPSO) | withdrawn | — | 0 | Pinnacle Biologics Inc.INDUSTRY | 0 | May 9, 2012 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials